4.8 Article

KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease

期刊

NATURE COMMUNICATIONS
卷 12, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41467-021-23755-z

关键词

-

资金

  1. DAAD
  2. Alzheimer Forschung Initiative (AFI) [15035]
  3. Legerlotz Stiftung
  4. LMUexcellent
  5. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) grant for major research instrumentation (DFG) [INST 409/193-1 FUGG]
  6. Hertie Foundation for Clinical Neurosciences
  7. European Union [666881, 667375]
  8. DFG as part of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy) [390857198, CRC 1123]
  9. ADNI (National Institutes of Health) [U01 AG024904]
  10. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  11. National Institute on Aging
  12. National Institute of Biomedical Imaging, and Bioengineering
  13. Alzheimer's Association
  14. Alzheimer's Drug Discovery Foundation
  15. Araclon Biotech
  16. BioClinica, Inc.
  17. Biogen
  18. Bristol-Myers Squibb Company
  19. CereSpir, Inc.
  20. Cogstate
  21. Eisai Inc.
  22. Elan Pharmaceuticals, Inc.
  23. Eli Lilly and Company
  24. EuroImmun
  25. F. Hoffmann-La Roche Ltd
  26. Genentech, Inc.
  27. Fujirebio
  28. GE Healthcare
  29. IXICO Ltd.
  30. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  31. Johnson & Johnson Pharmaceutical Research & Development LLC.
  32. Lumosity
  33. Lundbeck
  34. Merck Co., Inc.
  35. Meso Scale Diagnostics, LLC.
  36. NeuroRx Research
  37. Neurotrack Technologies
  38. Novartis Pharmaceuticals Corporation
  39. Pfizer Inc.
  40. Piramal Imaging
  41. Servier
  42. Takeda Pharmaceutical Company
  43. Transition Therapeutics
  44. Canadian Institutes of Health Research
  45. AbbVie
  46. LMU Forderung Forschung Lehre [1032]
  47. MRC [UKDRI-1001] Funding Source: UKRI

向作者/读者索取更多资源

The Klotho-VS haplotype is associated with reduced risk of Alzheimer's disease and dementia. This study demonstrates an association between the KL-VS haplotype and amyloid-dependent tau accumulation using PET data. KL-VShet carriers show lower levels of tau-PET per unit increase in amyloid-PET, suggesting a protective role against amyloid-related tau pathology and memory impairments in elderly individuals at risk of AD dementia.
Klotho-VS heterozygosity (KL-VShet) is associated with reduced risk of Alzheimer's disease (AD). However, whether KL-VShet is associated with lower levels of pathologic tau, i.e., the key AD pathology driving neurodegeneration and cognitive decline, is unknown. Here, we assessed the interaction between KL-VShet and levels of beta-amyloid, a key driver of tau pathology, on the levels of PET-assessed neurofibrillary tau in 551 controls and patients across the AD continuum. KL-VShet showed lower cross-sectional and longitudinal increase in tau-PET per unit increase in amyloid-PET when compared to that of non-carriers. This association of KL-VShet on tau-PET was stronger in Klotho mRNA-expressing brain regions mapped onto a gene expression atlas. KL-VShet was related to better memory functions in amyloid-positive participants and this association was mediated by lower tau-PET. Amyloid-PET levels did not differ between KL-VShet carriers versus non-carriers. Together, our findings provide evidence to suggest a protective role of KL-VShet against amyloid-related tau pathology and tau-related memory impairments in elderly humans at risk of AD dementia. The KL-VS haplotype of the Klotho gene has been associated with reduced risk of Alzheimer's disease and dementia. Here the authors show an association between the KL-VS haplotype and amyloid-dependent tau accumulation using PET data.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据